Blue Trust Inc. Acquires 143 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Blue Trust Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 808 shares of the company’s stock after purchasing an additional 143 shares during the quarter. Blue Trust Inc.’s holdings in Medpace were worth $270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the stock. State Street Corp raised its stake in shares of Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after buying an additional 50,312 shares during the period. Geode Capital Management LLC boosted its position in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after purchasing an additional 44,371 shares during the period. Wellington Management Group LLP increased its stake in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. American Capital Management Inc. raised its position in shares of Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after purchasing an additional 9,592 shares during the period. Finally, FMR LLC boosted its holdings in Medpace by 11.8% in the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after buying an additional 24,362 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Truist Financial cut their price target on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. Redburn Atlantic started coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $349.15 on Monday. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The company has a market cap of $10.85 billion, a P/E ratio of 30.57, a PEG ratio of 1.76 and a beta of 1.36. The firm has a 50-day simple moving average of $342.50 and a two-hundred day simple moving average of $351.96.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.